Cerus Corporation  

(Public, NASDAQ:CERS)   Watch this stock  
Find more results for Daniel R Laurence´┐Ż
5.24
+0.31 (6.29%)
Sep 4 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.85 - 5.27
52 week 3.60 - 7.03
Open 4.88
Vol / Avg. 949,865.00/854,820.00
Mkt cap 477.11M
P/E     -
Div/yield     -
EPS -0.67
Shares 96.78M
Beta 2.07
Inst. own 73%
Sep 17, 2015
Cerus Corp at Morgan Stanley Healthcare Conference - 8:00AM EDT - Add to calendar
Sep 9, 2015
Cerus Corp at Robert W Baird and Co Health Care Conference - 3:45PM EDT - Add to calendar
Aug 11, 2015
Cerus Corp at Wedbush PacGrow Healthcare Conference
Aug 6, 2015
Q2 2015 Cerus Corp Earnings Call
Aug 6, 2015
Q2 2015 Cerus Corp Earnings Release
Jul 8, 2015
Cerus Corp at Cantor Fitzgerald Inaugural Healthcare Conference
Jun 11, 2015
Cerus Corp Annual Shareholders Meeting (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -180.88% -106.42%
Operating margin -175.82% -122.21%
EBITD margin - -118.32%
Return on average assets -43.49% -46.93%
Return on average equity -58.12% -91.93%
Employees 144 -
CDP Score - -

Address

2550 Stanwell Dr
CONCORD, CA 94520-4813
United States - Map
+1-925-2886000 (Phone)
+1-925-2886001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cerus Corporation is a biomedical products company engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including HIV, West Nile, SARS, hepatitis B and C; bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company has commercial rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets or platelet system and the INTERCEPT Blood System for plasma or plasma system are being marketed and sold in a number of countries, including the United States, certain countries in Europe, The Commonwealth of Independent States (CIS) and the Middle East. The INTERCEPT Blood System for red blood cells is in development-stage.

Officers and directors

Daniel N. Swisher Jr. Independent Chairman of the Board
Age: 52
Bio & Compensation  - Reuters
William M. Greenman President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Kevin D. Green Chief Financial Officer, Vice President - Finance
Age: 43
Bio & Compensation  - Reuters
Caspar Hogeboom President, Cerus Europe and EEMEA
Age: 56
Bio & Compensation  - Reuters
Laurence M. Corash M.D. Senior Vice President, Chief Medical and Chief Scientific Officer, Director
Age: 71
Bio & Compensation  - Reuters
Carol M. Moore Senior Vice President - Regulatory Affairs, Quality and Clinical
Age: 65
Bio & Compensation  - Reuters
Richard J. Benjamin Chief Medical Officer
Bio & Compensation  - Reuters
Chrystal N. Menard Chief Legal Officer and General Counsel
Age: 44
Bio & Compensation  - Reuters
Timothy Bruce Anderson Independent Director
Age: 68
Bio & Compensation  - Reuters
Bruce C. Cozadd Independent Director
Age: 51
Bio & Compensation  - Reuters